Chairman & CEO
In 2002 I founded Viral Shield Pharmaceuticals, Inc., with an exclusive option to license 2-Hydroxypropyl beta cyclodextrin anti-viral technology from Johns Hopkins Medical Institutions. Over the past two years, we have met the following milestones:
Developed topical treatment products for Herpes labialis and Herpes genitalis. Phase IIA clinical trials will be conducted in Germany for Herpes genitalis and Hungary for Herpes labialis, starting in Q2, 2004, for European registration.
The first long-acting antiviral hand cream and skin lotion is currently under development.
Also under development are nasal/oral/pulmonary sprays for prevention and early treatment of Influenza, Parainfluenza and Respiratory Syncitial Virus (RSV)
Future efforts will develop microbicides to block the sexual transmission of:
Herpes Simplex Virus
Human Immunodeficiency Virus (HIV), Human Papilloma Virus (HPV) and Hepatitis B & C Virus (HBV, HCV).
Non-viral sexually transmitted diseases (STD), including Chlamydia, Trichomonas, Gonorrhea and Haemophilus ducreyi